DNB Related Funding Opportunities

Genetics, Epigenetics, and Developmental Neuroscience Branch (GEDN)

Program Announcements

  • PAR-22-133 – NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
  • PAR-21-244 – NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)
  • PAR-21-208 – Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) 
  • PAR-20-267 – NIDA Core “Center of Excellence” Grant Program (P30 Clinical Trial Optional) 
  • PAR-20-225 – Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) 
  • PAR-20-148 – Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21 – Clinical Trial Not Allowed) 
  • PAR-20-147 – Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01 – Clinical Trial Not Allowed) 
  • PAR-20-082 – Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) 
  • PAR-20-055 – Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
  • PA-20-047 – Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed) 
  • PA-20-025 – Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed) 
  • PAR-19-345 – NIDA Program Project Grant Applications (P01 Clinical Trial Optional) 

Requests for Application

  • RFA-AI-22-038 – A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention (P01 Clinical Trial Not Allowed) 
  • RFA-DA-23-012 – Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) 
  • RFA-DA-23-004 – Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 – Clinical Trial Not Allowed) 
  • RFA-DA-23-003 – Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 – Clinical Trial Optional)
  • RFA-DA-22-004 - Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
  • RFA-DA-22-040 High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  • RFA-DA-22-010 – Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01 – Clinical Trial Optional)
  • RFA-DA-21-006 – BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 – Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-DA-23-004– Notices of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior
  • NOT-DA-21-020 Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use
  • NOT-DA-20-039 – Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain 
  • NOT-DA-20-031 – Notice of Special Interest (NOSI): Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders 
  • NOT-DA-20-030 – Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders 
  • NOT-NS-20-024 – Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) – U.S. Entity (Admin Supp) 
  • NOT-DA-20-020 – Notice of Special Interest (NOSI): Going Global: Using Gene Network Analyses to Understand the Etiology of SUD 
  • NOT-DA-20-018 – Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes 

Chemistry and Pharmacology Branch (CP)

Program Announcements

  • PAR-20-253 – Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
  • PAR-22-032 – Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) 
  • PAR-22-031 – Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed)
  • PAR-21-029 – Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) 
  • PAR-21-028 – Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed) 

Requests for Application

  • RFA-DA-23-014 – Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1 – Clinical Trial Not Allowed)
  • RFA-TR-22-011 – Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Withing the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) 
  • RFA-NS-21-010 – HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) 

Notices of Special Interest (NOSI)

  • NOT-DA-23-002 – Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs 
  • NOT-DA-21-033 – Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology 
  • NOT-DA-21-028 – Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects 

Behavioral and Cognitive Neuroscience Branch (BCN)

Program Announcements

  • PAR-21-352 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required) 
  • PAR-21-350 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed) 
  • PAR-21-349 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required) 
  • PAR-21-309 – Imaging – Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required) 
  • PAR-21-310 – Imaging – Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional) 
  • PAR-21-281 – Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Clinical Trials Not Allowed) 
  • PAR-21-280 – Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 – Basic Experimental Studies with Humans) 
  • PAR-19-282 – Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) 

Requests for Application

  • RFA-DA-23-027 – Workshops on Computational and Analytical Research Methods (R25 – Clinical Trial Not Allowed) 
  • RFA-OD-21-004 – Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed) 
  • RFA-OD-21-003 – Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) 
  • RFA-OD-21-002 - Tobacco Regulatory Science (R01 Clinical Trial Optional) 
  • RFA-OD-20-011 – Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Required)
  • RFA-OD-20-010 – Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Required) 
  • RFA-OD-20-009 – Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Not Allowed) 
  • RFA-OD-20-008 – Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-OD-22-022 – Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-012 - Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence 
  • NOT-AT-21-002 – Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease 
  • NOT-DA-20-007 – Notice of Special Interest (NOSI): Preclinical and Clinical Studies of the Interactions of Opioids and Stimulants 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience 
  • NOT-DA-20-017 – Notice of Special Interest (NOSI): Harnessing computational tools for sophisticated analyses of Substance Use Disorder-related behaviors 
  • NOT-DA-20-006 – Notice of Special Interest (NOSI): Mentored Career Development Award in Large-Scale Clinical Study Development and Analysis 
  • NOT-DA-20-005 – Notice of Special Interest (NOSI): Mechanistic Investigations of Psychosocial Factors Associated with Substance Use Disorders 
  • NOT-DA-21-003 - Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder 

Notices

  • NOT-OD-22-084 – Notice of Intent to Publish the Reissuance of RFA-OD-20-010, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Required) 
  • NOT-OD-22-083 – Notice of Intent to Publish the Reissuance of RFA-OD-20-009, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Not Allowed) 
  • NOT-OD-22-082 - Notice of Intent to Publish the Reissuance of RFA-OD-20-011, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Required) 
  • NOT-OD-22-081 – Notice of Intent to Publish the Reissuance of RFA-OD-20-008, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Not Allowed) 

Integrative Neuroscience Branch

Program Announcements

  • PAR-20-249 – NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) 
  • PA-20-151 – Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed) 
  • PA-20-149 – HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed) 
  • PAS-21-270 – AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) 
  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Requests for Application

  • RFA-DA-23-001 – Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional) 
  • RFA-DA-22-004 - Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
  • RFA-DA-23-015 – Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 – Clinical Trial Not Allowed) 
  • RFA-AI-22-025 – Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed) 

Notices of Special Interest (NOSI)

  • NOT-DA-22-058 – Notices of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior 
  • NOT-DA-22-047 – Notice of Special Interest (NOSI): Mechanistic studies on the impact of substance use in sex and gender differences in HIV-associated neurocognitive disorders 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-006 - Notice of Special Interest (NOSI): Leveraging transformative connectome resources in model organisms to elucidate the neurobiology of substance use disorders 
  • NOT-DA-21-014 - Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity 
  • NOT-DA-21-001 – Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain 
  • NOT-DA-20-060 – Notice of Special Interest (NOSI): Role of Astrocytes and Astrocytic Networks in Drug Abuse 
  • NOT-DA-20-046 – Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience 
  • NOT-DA-20-021 – Notice of Special Interest (NOSI): Sleep and Substance Use Disorders 

Notices

  • NOT-DA-22-070 – Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) 
  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, “NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)” 

Office of the Director

Program Announcements

  • PAR-22-133 – NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) 
  • PAR-20-097 – Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed) 
  • PAR-20-089 – Biomedical Data Repository (U24 – Clinical Trials Not Allowed) 
  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Notices of Special Interest (NOSI)

  • NOT-MH-21-175 – Notice of Special Interest (NOSI) regarding the use of Human Connectome Data for Secondary Analysis 
  • NOT-AI-21-054 – Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-013 – Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research 
  • NOT-DA-21-004 – Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction 
  • NOT-DA-23-006 – Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience 
  • NOT-DA-20-009 – Notice of Special Interest (NOSI): Modeling Social Contagion of Substance Use Epidemics 

Notices

  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, “NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)”